FIA
ACIU icon

FNY Investment Advisers’s AC Immune ACIU Stock Holding History

FNY Investment Advisers’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,625
Closed -$7K – 595
2023
Q2 		$7K Buy
+2,625
New +$5.73K 0.01% 338

Other funds holding ACIU

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

FNY Investment Advisers's ACIU Position: Q3 2023 in Review

FNY Investment Advisers sold out of AC Immune (ACIU) in Q3 2023, closing a stake of 2,625 shares — an estimated $7K sold.

FNY Investment Advisers first reported a position in ACIU in Q2 2023 and held it in 1 quarter. The position peaked at $7K in Q2 2023. 28 funds tracked by Wall St. Rank hold ACIU as of Q3 2023.

  • FNY Investment Advisers reported no remaining AC Immune position as of Q3 2023 after selling out during the quarter.
  • FNY Investment Advisers sold 2,625 AC Immune shares in Q3 2023, an estimated $7K.
  • FNY Investment Advisers first reported a position in AC Immune in Q2 2023 and held it in 1 quarter.
  • FNY Investment Advisers's AC Immune position peaked at $7K in Q2 2023.
  • 28 funds tracked by Wall St. Rank held AC Immune as of Q3 2023.

Based on FNY Investment Advisers's 13F filing for Q3 2023, filed 10 Oct 2023.